




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 5/12, A61K 38/07	A2	(11) International Publication Number: WO 00/08048 (43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/JP99/04148 (22) International Filing Date: 2 August 1999 (02.08.99) (30) Priority Data: PP 5057 4 August 1998 (04.08.98) AU (71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): MORI, Hiroaki [JP/JP]; 5-20-205, Ohmachi, Tsuchiura-shi, Ibaraki 300-0038 (JP). ABE, Fumie [JP/JP]; 2-21-2-1-501, Matsushiro, Tsukuba-shi, Ibaraki 305-0035 (JP). YOSHIMURA, Seiji [JP/JP]; 4-21-2-1-404, Matsushiro, Tsukuba-shi, Ibaraki 305-0035 (JP). TAKASE, Shigehiro [JP/JP]; 1-12-10, Sousha, Ishioka-shi, Ibaraki 315-0016 (JP). HINO, Motohiro [JP/JP]; 13-3-1003, Touzaki-cho, Tsuchiura-shi, Ibaraki 300-0031 (JP). (74) Agent: TABUSHI, Eiji; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).		(81) Designated States: BR, CA, CN, JP, KR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published Without international search report and to be republished upon receipt of that report.

(54) Title: INHIBITOR OF HISTONE DEACETYLASE



(I)

(57) Abstract

The present invention provides a new compound of formula (I) which has a histone deacetylase inhibiting activity, and a process for production thereof. Also provided is a pharmaceutical composition containing the compound for treating or preventing organ transplant rejections, autoimmune diseases, tumors, and the like.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroun	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION

INHIBITOR OF HISTONE DEACETYLASE

5 TECHNICAL FIELD

The present invention relates to a novel cyclic tetrapeptide compound, hereinafter entitled FR225497 substance which is useful as a medicament, to process for producing the same and to pharmaceutical composition comprising
10 the same.

BACKGROUND ART

European Patent Application of EP0406725 discloses that Helicoma
15 ambiens RF-1023 (FERM BP-2751) produces RF-1023-A (Trapoxin A) and RF-1023-B (Trapoxin B).

DISCLOSURE OF INVENTION

20 The present invention relates to a novel cyclic tetrapeptide compound, FR225497 substance.

More particularly, it relates to novel cyclic tetrapeptide compound, FR225497 substance, which is obtained from the culture broth of Helicoma
ambiens RF-1023-1. In this respect, Helicoma ambiens RF-1023-1 is
25 subculture of Helicoma ambiens RF-1023 (FERM BP-2751).

Now, we found FR225497 substance which is structurally related compound with RF-1023-A (Trapoxin A) and RF-1023-B (Trapoxin B). Compared with Trapoxin A and Trapoxin B, the FR225497 substance is
30 markedly stable at the incubation with rat liver S-9 fraction. Therefore, FR225497 substance is considered to be strongly more effective than Trapoxin A or Trapoxin B.

The FR225497 substance has potent inhibitory effect on activity of histone deacetylase. Histone deacetylases are known to play an essential role

in the transcriptional machinery for regulating gene expression, and histone deacetylase inhibitors induce histone hyperacetylation and affect the gene expression. Therefore, histone deacetylase inhibitor, such as the FR225497 substance, is considered to be useful as a therapeutical or prophylactic agent for
5 several diseases caused by abnormal gene expression such as inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), protozoal infection, or the like.

We also found histone deacetylase inhibitor, such as the FR225497 substance, has potent immunosuppressive effect and potent antitumor effect.
10 Therefore, histone deacetylase inhibitor, such as FR225497 substance, is useful for an active ingredient of an immunosuppressant and an antitumor agent and useful as a therapeutical or prophylactic agent for an organ transplant rejection, autoimmune diseases, tumor, or the like.

Accordingly, one object of this invention is to provide a novel
15 compound FR225497 substance which has biological activities stated above.

Another object of this invention is to provide a process for production of FR225497 substance by fermentation of a FR225497 substance-producing strain belonging to the Helicoma in a nutrient medium.

A further object of this invention is to provide a pharmaceutical
20 composition containing, as an active ingredient, the FR225497 substance.

Still further object of this invention is to provide a use of the histone deacetylase inhibitors, such as FR225497 substance, for treating and preventing diseases stated above.

25 The FR225497 substance can be produced by fermentation of the FR225497 substance-producing strain belonging to the Helicoma such as Helicoma ambiens RF-1023-1.

It is to be understood that the production of the FR225497 substance is
30 not limited to the use of the particular organism described herein, which is given for the illustrative purpose only. This invention also includes the use of any mutants which are capable of producing the FR225497 substance including natural mutants as well as artificial mutants which can be produced from the described organism by conventional means such as irradiation of X-ray, ultra-

violet radiation, treatment with N-methyl-N'-nitro-N-nitrosoguanidine, 2-aminopurine, and the like.

This strain was deposited in National Institute of Bioscience and Human-
5 Technology, Agency of Industrial Science and Technology (1-3, Higashi 1-
chome, Tsukuba-shi, Ibaraki, Japan) as Helicoma ambiens RF-1023-1 (FERM
BP-6413 (deposition date: July 9, 1998)).

Production of the FR225497 substance

10

The FR225497 substance is produced when the FR225497 substance-
producing strain belonging the Helicoma is grown in a nutrient medium
containing sources of assimilable carbon and nitrogen under aerobic conditions
(e. g. shaking culture, submerged culture, etc.). .

15

The preferred sources of carbon in the nutrient medium are carbohydrates
such as glucose, sucrose, starch, fructose or glycerin, or the like.

20

The preferred sources of nitrogen are peanut powder, yeast extract, beef
extract, peptone, polypeptone, gluten meal, cotton seed flour, soybean powder,
soybean meal, corn steep liquor, dried yeast, wheat germ, etc., as well as
inorganic and organic nitrogen compounds such as ammonium salts (e. g.
ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea or
amino acid, or the like.

25

The carbon and nitrogen sources, though advantageously employed in
combination, need not to be used in their pure form because less pure materials,
which contain traces of growth factors and considerable quantities of mineral
nutrients, are also suitable for use.

30

When desired, there may be added to the medium mineral salts such as
sodium or calcium carbonate, sodium or potassium phosphate, sodium or
potassium chloride, sodium or potassium iodide, magnesium salts, copper salts,
zinc salts, iron salts, or cobalt salts, or the like.

If necessary, especially when the culture medium foams seriously a
defoaming agent, such as liquid paraffin, fatty oil, plant oil, mineral oil or
silicone, or the like may be added.

Agitation and aeration of the culture mixture may be accomplished in a

variety of ways, such as agitation by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermenter, and the like.

The fermentation is usually conducted at a temperature between about 10°C and 40°C, preferably 20°C to 30°C, for a period of about 50 hours to 150 hours, which may be varied according to fermentation conditions and scales.

When the fermentation is completed, the culture broth is then subjected for recovery of the FR225497 substance to various procedures conventionally used for recovery and purification of biological active substance, for instance, solvent extraction with an appropriate solvent or a mixture of some solvents, chromatography or recrystallization from an appropriate solvent or a mixture thereof.

The FR225497 substance as obtained has the following physico-chemical properties:

15

Appearance:

white powder

Molecular formula :

$C_{34}H_{44}N_4O_5$

20

Elementary Analysis:

Calcd for $C_{34}H_{44}N_4O_5 \cdot 1/2 H_2O$

C 68.32, H 7.59, N 9.35

Found:

C 68.61, H 7.52, N 9.37

25

Molecular weight:

ESI-MS (+): m/z 589 (M + H)⁺

ESI-MS (-): m/z 587 (M - H)⁻

Melting point:

193-194 °C

30

Specific rotation:

$[\alpha]_D^{23} -64^\circ$ (c=0.5, in chloroform)

Ultraviolet absorption spectrum:

λ_{max} (methanol): 235 (sh) nm

λ_{max} (methanol+NaOH): 235 (sh) nm

Solubility:

Soluble: methanol, chloroform, ethyl acetate

Insoluble: water, n-hexane

Color reaction:

5 Positive: ceric sulfate reaction, iodine vapor reaction

Negative: ninhydrin reaction, ferric chloride reaction, Molish reaction,
Ehrlich reaction, Dragendorff reaction**Thin layer chromatography (TLC):**

	Stationary phase	Developing solvent	Rf value
10	Silica Gel 60 F254*	chloroform:methanol (20:1, v/v)	0.66

* made by E. Merck

High Performance Liquid Chromatography (HPLC):**Condition:**

15 Mobile phase: acetone:water=50:50

Column: YMC ODS AM-303** (250 x 4.6 mm i. d.)

Flow rate: 1.0 ml/minute

Detection: UV at 210 nm

Retention time: 15.3 minutes

20 ** trade name: made by Yamamura Chemical Institute

Infrared Spectrum: ν_{\max} (KBr): 3340, 3320, 2930, 1710, 1690, 1670, 1660, 1630, 1530,
1510, 1420, 1310, 1170, 1110 cm^{-1} **^1H Nuclear magnetic resonance spectrum:**25 (500 MHz, CDCl_3) δ_{H} 7.45 (1H, d, $J=10\text{Hz}$, exchangeable), 7.32 - 7.18 (8H, m), 7.12 - 7.09 (2H, m),
6.44 (1H, d, $J=10\text{Hz}$, exchangeable), 6.37 (1H, d, $J=6\text{Hz}$, exchangeable), 5.35
(1H, m), 5.01 (1H, m), 4.16 (1H, m), 3.94 (1H, m), 3.75 - 3.63 (2H, m), 3.28 -
3.18 (2H, m), 3.10 - 2.98 (2H, m), 2.43 - 2.34 (4H, m), 2.08 (1H, m), 1.97 (1H,
30 m), 1.78 (1H, m), 1.72 (1H, m), 1.54 - 1.47 (5H, m), 1.32 - 1.16 (5H, m), 1.06
(3H, t, $J=7\text{Hz}$) **^{13}C Nuclear magnetic resonance spectrum:**(125 MHz, CDCl_3) δ_{C}


211.5 (s), 175.8 (s), 173.6 (s), 173.3 (s), 171.4 (s), 137.0 (s), 137.0 (s), 129.1 (d)

x2, 128.9 (d) x2, 128.6 (d) x2, 128.5 (d), x2, 126.9 (d), 126.7 (d), 62.9 (d), 53.5 (d), 50.9 (d), 50.0 (d), 43.9 (t), 42.1 (t), 36.5 (t), 35.9 (t), 35.2 (t), 29.0 (t), 28.7 (t), 25.2 (t), 25.1 (t), 24.0 (t), 23.5 (t), 19.2 (t), 7.8 (q)

Nature:

5 Neutral substance

From the above physico-chemical properties and extensive studies, the chemical structure of FR225497 substance was assigned as follows.



20 FR225497 substance can be in a form of a solvate, which is included within the scope of the present invention. The solvate preferably include a hydrate and an ethanolate.

25 As examples for showing biological activities of the FR225497 substance, some biological data are explained in the following.

Test 1: Effect of FR225497 substance on lymphocyte blastogenic response

30 The lymphocyte blastogenesis test was performed in microtiter plates with each well containing 1×10^5 splenic cells of Balb/c mice in 0.1 ml RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 50mM 2-mercaptoethanol, penicillin (100 units/ml) and streptomycin (100 μ g/ml), to which anti-CD3 antibody (2C11) (1 μ g/ml) was added. The cells were incubated at 37°C in a humidified atmosphere of 5% CO₂ for 72 hours. After the culture period, suppressive activities of the test samples in lymphocyte blastogenesis

were quantified by a MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] dye reduction assay.

FR225497 substance was dissolved in methanol and further diluted in RPMI- 1640 medium and added to the culture to give final concentrations of
5 1250 ng/ml or less.

The results are shown in Table 1.

As shown in Table 1, FR225497 substance suppressed murine lymphocyte blastogenesis induced by anti- CD3 antibody in a dose-dependent manner.

10

Table 1 Effect of FR225497 substance on murine lymphocyte blastogenesis induced by anti-CD3 antibody

15	Concentration (ng/ml)	1250	625	313	156	78	39	20	10
	Inhibition (%)	116.2	116.6	117.3	115.7	96.1	44.8	3.9	1.6

20 Test 2: Effect of FR225497 substance on DTH (delayed type hypersensitivity) response in mice

Female Balb/c mice were immunized with sheep red blood cells (1×10^8) by subcutaneous injection. FR225497 substance was dissolved in olive oil and administered subcutaneously for 8 consecutive days, beginning at one day before
25 the immunization. Six days after the immunization, sheep red blood cells (1.25×10^8) were injected into right rear foot pad, and 24 hours later, footpad swelling was measured with dial guage (Ozaki MFG Co.,LTD.). The magnitude of the DTH was expressed as the thickness of the challenged right footpad as compared with the untreated left footpad.

30 As shown in Table 2, the footpad swelling was markedly suppressed by the administration of FR225497 substance in a dose-dependent manner without any body weight loss.

Table 2 Effect of FR225497 substance on DTH response in mice

	N	Dose (mg/kg)	Foot pad swelling (% Inhibition)	Body weight gain (g)
5	unprimed	5	100***	2.3±0.3***
	primed (olive oil)	10	0	3.4±0.1
	FR225497	5	0.1	2.5±0.1***
	substance	5	1.0	3.8±0.3
		5	10	4.0±0.3
10			** : P<0.01	*** : P<0.001

Test 3: Incubation of FR225497 substance with rat liver S-9 fraction

15 A solution of 1 mg/ml of FR225497 substance was prepared in methanol. Ten μ l of the solution was added to 990 μ l of the solution of the rat liver S-9 fraction (0.8 mg protein/ml ; Oriental Yeast Co., LTD.) containing cofactors ($\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$: 8 μ mol, KCl : 33 μ mol, glucose 6-phosphate : 5 μ mol, NADPH : 4 μ mol, NADH : 4 μ mol and $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ / $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$: 100 μ mol ; Oriental Yeast Co., LTD.) in a test tube (1.5 ml tube ; BIO-BIC).

20 The solution mixture in the test tube was incubated for 30 minutes at 37°C in a shaking bath. Appropriate blanks without S-9 protein and cofactors were incubated in the same manner.

After the incubation, 300 μ l of the solution mixture was placed in a screw-cap test tube, and the reaction was terminated by the addition of 300 μ l of methanol and 1500 μ l of phosphate-buffered saline. After mixing vigorously for 10 sec., the remaining FR225497 substance was extracted with 3000 μ l of ethyl acetate, 2000 μ l of organic phase was placed in another test tube, and the ethyl acetate gently evaporated with a stream of nitrogen. Two-hundred μ l of methanol was added, and the concentration of the FR225497 substance was

30 analyzed by analytical HPLC indicated below. Trapoxin A and Trapoxin B were also tested in the same manner.

As shown in Table 3, compared with Trapoxin A and Trapoxin B, FR225497 substance was markedly stable at the incubation with S-9 protein and cofactors.

Table 3 Incubation of Trapoxin A, Trapoxin B and FR225497 substance with rat liver S-9 fraction

5	Remaining (%)		
	Trapoxin A	Trapoxin B	FR225497 substance
	0	3.3	95.2

10 (analytical HPLC condition)

column YMC Pack ODS-AM AM303 , S-5 120A
(250 mm L. x 4.6 mm ID, YMC Co., Ltd.)
eluent 50% aqueous acetonitrile
flow rate 1 ml/minute.
15 detection UV at 210 nm
retention time FR225497 substance 12.3 minutes.

Test 4: Effect of FR225497 substance on activity of partially purified human histone deacetylase

20

The partial purification of human histone deacetylase, the preparation of [3H] acetyl histones, and the assay for histone deacetylase activity were basically according to the method as proposed by Yoshida et al. (Yoshida, M. et al.: J. Biol. Chem., 265:17174-17179, 1990) as follows.

25 Partial Purification of Human Histone Deacetylase:

The human histone deacetylase was partially purified from human T cell leukemia Jurkat cells. Jurkat cells (5×10^8 cells) were suspended in 40 ml of the HDA buffer consisting of 15 mM potassium phosphate, pH 7.5, 5% glycerol and 0.2 mM EDTA. After homogenization, nuclei were collected by centrifugation
30 (35,000 x g, 10 minutes) and homogenized in 20 ml of the same buffer supplemented with 1 M $(\text{NH}_4)_2\text{SO}_4$. The viscous homogenate was sonicated and clarified by centrifugation (35,000 x g, 10 minutes), and the deacetylase was precipitated by raising the concentration of $(\text{NH}_4)_2\text{SO}_4$ to 3.5 M. The precipitated protein was dissolved in 10 ml of the HDA buffer and dialyzed

against 4 liters of the same buffer. The dialyzate was then loaded onto a DEAE-cellulose (Whatman DE52) column (25 x 85 mm) equilibrated with the same buffer and eluted with 300 ml a linear gradient (0-0.6 M) of NaCl. A single peak of histone deacetylase activity was eluted between 0.3 and 0.4 M NaCl.

5 Preparation of [^3H] Acetyl Histones:

To obtain [^3H]acetyl-labeled histones as the substrate for the histone deacetylase assay, 1×10^8 cells of Jurkat in 20 ml of RPMI-1640 medium supplemented with 10% FBS, penicillin (50 units/ml) and streptomycin (50 $\mu\text{g/ml}$) were incubated with 300 MBq [^3H] sodium acetate in the presence of 5 mM sodium butyrate for 30 minutes in 5% CO_2 -95% air atmosphere at 37°C in a 75 cm^2 flask, harvested into a centrifuge tube (50 ml), collected by centrifugation at 1000 rpm for 10 minutes, and washed once with phosphate-buffered saline. The washed cells were suspended in 15 ml of ice-cold lysis buffer (10 mM Tris-HCl, 50 mM sodium bisulfite, 1% Triton X-100, 10 mM 15 MgCl_2 , 8.6% sucrose, pH 6.5). After Dounce homogenization (30 stroke), the nuclei were collected by centrifugation at 1000 rpm for 10 minutes, washed three times with 15 ml of the lysis buffer, and once with 15 ml of ice-cold washing buffer (10 mM Tris-HCl, 13 mM EDTA, pH 7.4) successively. The pellet was suspended in 6 ml of ice-cold water using a mixer, and 68 ml of 20 H_2SO_4 was added to the suspension to give a concentration of 0.4 N. After incubation at 4°C for 1 hour, the suspension was centrifuged for 5 minutes at 15,000 rpm, and the supernatant was taken and mixed with 60 ml of acetone. After overnight incubation at -20°C, the coagulated material was collected by microcentrifugation, air-dried, and stored at -80°C.

25 Assay for Histone Deacetylase Activity:

For the standard assay, 10 μl of [^3H]acetyl-labeled histones were added to 90 μl of the enzyme fraction, and the mixture was incubated at 25°C for 30 minutes. The reaction was stopped by addition of 10 μl of HCl. The released [^3H]acetic acid was extracted with 1 ml of ethyl acetate, and 0.9 ml of the 30 solvent layer was taken into 10 ml of toluene scintillation solution for determination of radioactivity.

As shown in Table 4, FR225497 substance potently inhibited the activity of partially purified human (Jurkat cells) histone deacetylase in a dose-dependent manner.

Table 4 Effect of FR225497 substance on activity of partially purified human histone deacetylase

5	Concentration (ng/ml)	1000	100	10	1
	Inhibition (%)	91.7	67.5	33.4	8.12

10

Test 5: Antitumor activities of FR225497 substance against human tumor cell lines

15 The cytotoxic activity of FR225497 substance against human tumor cell lines in vitro was determined as follows. Concentration of the compound required for 50% inhibition of cell growth (IC₅₀; ng/ml) was examined by plotting the logarithms of the concentration vs. the growth rate (percentage of control) of the treated cells. Human T cell leukemia Jurkat cells (1 x 10⁵ cells/ml) and human colon adenocarcinoma HT-29 cells (5 x 10⁴ cells/ml) were
20 treated with FR225497 substance in 100 µl of RPMI-1640 medium supplemented with 10% FBS, penicillin (50 units/ml) and streptomycin (50 µg/ml) in 5% CO₂-95% air atmosphere at 37°C. The cytotoxicity was colorimetrically determined at 550 nm (and 660 nm as a reference) according to the MTT method described above.

25 The result was shown in Table 5. FR225497 substance had potent antitumor activities against Jurkat cells and HT-29 cells.

Table 5 Antitumor activities of FR225497 substance against human tumor cell lines (in vitro)

30

IC ₅₀ (ng/ml)	
Jurkat	HT-29
152	158

The pharmaceutical composition of this invention comprising FR225497 is useful as a therapeutic or prophylactic agent for diseases caused by abnormal gene expression such as inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukemia (APL), protozoal infection or the like. Further, it is useful as an antitumor agent and immunosuppressant, which prevent an organ transplant rejection and autoimmune diseases as exemplified below.

Rejection reactions by transplantation of organs or tissues such as the heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limb, muscle, nerve, intervertebral disc, trachea, myoblast, cartilage, etc.; graft-versus-host reactions following bone marrow transplantation; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, etc.; and infections caused by pathogenic microorganisms (e.g. *Aspergillus fumigatus*, *Fusarium oxysporum*, *Trichophyton asteroides*, etc.).

Furthermore, pharmaceutical preparations of FR225497 are useful for the therapy and prophylaxis of the following diseases.

Inflammatory or hyperproliferative skin diseases or cutaneous manifestations of immunologically-mediated diseases (e.g. psoriasis, atopic dermatitis, contact dermatitis, eczematoid dermatitis, seborrheic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, erythema, dermal eosinophilia, lupus erythematosus, acne, and alopecia areata); autoimmune diseases of the eye (e.g. keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca (dry eye), phlyctenule, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, etc.); reversible obstructive airways diseases [asthma (e.g. bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, and dust asthma), particularly chronic or inveterate asthma (e.g. late asthma and airway hyper-responsiveness)]

- bronchitis, etc.];
mucosal or vascular inflammations (e.g. gastric ulcer, ischemic or thrombotic vascular injury, ischemic bowel diseases, enteritis, necrotizing enterocolitis, intestinal damages associated with thermal burns, leukotriene B4-mediated diseases);
5 intestinal inflammations/allergies (e.g. coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease and ulcerative colitis);
food-related allergic diseases with symptomatic manifestation remote from the gastrointestinal tract (e.g. migraine, rhinitis and eczema);
10 renal diseases (e.g. interstitial nephritis, Goodpasture's syndrome, hemolytic uremic syndrome, and diabetic nephropathy);
nervous diseases (e.g. multiple myositis, Guillain-Barre syndrome, Meniere's disease, multiple neuritis, solitary neuritis, cerebral infarction, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and
15 radiculopathy);
cerebral ischemic diseases (e.g., head injury, hemorrhage in brain (e.g., subarachnoid hemorrhage, intracerebral hemorrhage), cerebral thrombosis, cerebral embolism, cardiac arrest, stroke, transient ischemic attack (TIA), and hypertensive encephalopathy);
20 endocrine diseases (e.g. hyperthyroidism, and Basedow's disease);
hepatic diseases (e.g. pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, and anerythroplasia);
bone diseases (e.g. osteoporosis);
25 respiratory diseases (e.g. sarcoidosis, pulmonary fibrosis, and idiopathic interstitial pneumonia);
skin diseases (e.g. dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photosensitivity, and cutaneous T-cell lymphoma);
circulatory diseases (e.g. arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, and myocardosis);
30 collagen diseases (e.g. scleroderma, Wegener's granuloma, and Sjogren's syndrome);
adiposis;
eosinophilic fasciitis;

- periodontal diseases (e.g. damage to gingiva, periodontium, alveolar bone or substantia ossea dentis);
nephrotic syndrome (e.g. glomerulonephritis);
male pattern alopecia, alopecia senile;
- 5 muscular dystrophy;
pyoderma and Sezary syndrome;
chromosome abnormality-associated diseases (e.g. Down's syndrome);
Addison's disease;
active oxygen-mediated diseases [e.g. organ injury (e.g. ischemic circulation
- 10 disorders of organs (e.g. heart, liver, kidney, digestive tract, etc.) associated with
preservation, transplantation, or ischemic diseases (e.g. thrombosis, cardiac
infarction, etc.)];
intestinal diseases (e.g. endotoxin shock, pseudomembranous colitis, and drug-
or radiation-induced colitis);
- 15 renal diseases (e.g. ischemic acute renal insufficiency, chronic renal failure);
pulmonary diseases (e.g. toxicosis caused by pulmonary oxygen or drugs (e.g.
paracort, bleomycin, etc.), lung cancer, and pulmonary emphysema);
ocular diseases (e.g. cataracta, iron-storage disease (siderosis bulbi), retinitis,
pigmentosa, senile plaques, vitreous scarring, corneal alkali burn);
- 20 dermatitis (e.g. erythema multiforme, linear immunoglobulin A bullous
dermatitis, cement dermatitis);
and other diseases (e.g. gingivitis, periodontitis, sepsis, pancreatitis, and
diseases caused by environmental pollution (e.g. air pollution), aging,
carcinogen, metastasis of carcinoma, and hypobaropathy)];
- 25 diseases caused by histamine release or leukotriene C4 release;
restenosis of coronary artery following angioplasty and prevention of
postsurgical adhesions;
Autoimmune diseases and inflammatory conditions (e.g., primary mucosal
edema, autoimmune atrophic gastritis, premature menopause, male sterility,
- 30 juvenile diabetes mellitus, pemphigus vulgaris, pemphigoid, sympathetic
ophthalmitis, lens-induced uveitis, idiopathic leukopenia, active chronic
hepatitis, idiopathic cirrhosis, discoid lupus erythematosus, autoimmune orchitis,
arthritis (e.g. arthritis deformans), or polychondritis);
Human Immunodeficiency Virus (HIV) infection, AIDS;

allergic conjunctivitis;
hypertrophic cicatrix and keloid due to trauma, burn, or surgery.

Therefore, the pharmaceutical composition of the present invention is
5 useful for the therapy and prophylaxis of liver diseases [e.g. immunogenic
diseases (e.g. chronic autoimmune liver diseases such as autoimmune hepatic
diseases, primary biliary cirrhosis or sclerosing cholangitis), partial liver
resection, acute liver necrosis (e.g. necrosis caused by toxins, viral hepatitis,
shock, or anoxia), hepatitis B, non-A non-B hepatitis, hepatocirrhosis, and
10 hepatic failure (e.g. fulminant hepatitis, late-onset hepatitis and "acute-on-
chronic" liver failure (acute liver failure on chronic liver diseases))].

The pharmaceutical composition of this invention can be used in the
form of pharmaceutical preparation, for example, in solid, semisolid or liquid
15 form, which contains the FR225497, as an active ingredient in admixture with
an organic or inorganic carrier or excipient suitable for external, enteral or
parenteral administrations. The active ingredient may be compounded, for
example, with the usual non-toxic, pharmaceutically acceptable carriers for
tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions,
20 injections, ointments, liniments, eye drops, lotion, gel, cream, and any other
form suitable for use.

The carriers which can be used are water, glucose, lactose, gum acacia,
gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin,
25 colloidal silica, potato starch, urea and other carriers suitable for use in
manufacturing preparations, in solid, semisolid, or liquid form, and in addition
auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes
may be used.

30 For applying the composition to human, it is preferable to apply it by
intravenous, intramuscular, topical or oral administration. While the dosage of
therapeutically effective amount of the FR225497 substance varies from and
also depends upon the age and condition of each individual patient to be treated,
in the case of individual patient to be treated, in the case of intravenous

administration, a daily dose of 0.01 - 10 mg of the FR225497 substance per kg weight of human being, in the case of intramuscular administration, a daily dose of 0.1 - 10 mg of the FR225497 substance per kg weight of human being, in case of oral administration, a daily dose of 0.5 - 50 mg of the FR225497 substance of human being is generally given for treating.

THE BEST MODE OF CARRYING OUT OF THE INVENTION

Following examples are given for the purpose of illustrating the present invention in more detail.

EXAMPLE

(1) Fermentation of FR225497 substance :

15

An aqueous seed medium (160 ml) containing 1.0% polypeptone, 2.0% glucose, 0.3% beef extract, 0.2% yeast extract, 0.1% NaCl (pH 7.0) was poured into a 500-ml Erlenmeyer flask and sterilized at 120°C for 30 minutes. A slant culture (POTETO DEXTROSE AGER (Difco 0013)) of the strain Helicoma ambiens RF-1023-1 was inoculated into the flask and cultured at 28°C on a rotary shaker at 120 rpm (7 cm stroke) for 5-6 days. The seed culture (800 ml; 5 flasks) was inoculated to 20 liters of sterile production medium consisting of 2.0% potato starch, 2.0% sucrose, 0.5% yeast extract, 0.05% Adekanol LG-109 (defoaming agent, Asahi Denka Co., Ltd.) and 0.05% Silicone KM-70 (defoaming agent, Shin-Etsu Chemical Co., Ltd.) (pH 7.0) in a 30-liter jar fermentor. Fermentation was carried out at 25°C for 14 days under aeration of 20 liters/minutes and agitation of 150 rpm.

The production of active compound in the fermentation broth was monitored by HPLC analysis.

(analytical HPLC condition)

column	YMC Pack ODS-AM AM303 , S-5 120A (250mm L. x 4.6 mm I.D., YMC Co., Ltd.)
eluent	50% aqueous acetonitrile
flow rate	1 ml/minute.

detection UV at 210 nm
retention time FR225497 substance 12.3 minutes.


(2) Isolation of FR225497 substance :

5 The cultured broth (75L: containing 736 mg of FR225497 substance)
was extracted with 75L of acetone by intermittent mixing. The acetone extract
was filtered with an aid of diatomaceous earth and diluted with the same volume
of water. The diluted filtrate was passed through a column (15L) of Diaion HP-
20 (Mistubishi Chemical Co., Ltd.). The column was washed with water and
10 50% aqueous methanol, and eluted with methanol. The eluate (90L) was
concentrated in vacuo to give an oily residue (containing 506 mg of FR225497
substance) .

 The oily residue was dissolved in small volume of methanol and
applied on a column (4L) of YMC GEL ODS-AM 120-S50 (YMC Co., Ltd.)
15 packed with 50% aqueous acetonitrile. The column was eluted with 50%
aqueous acetonitrile and elution was monitored by analytical HPLC indicated
above. The portion corresponding to the purified FR225497 substance was
concentrated in vacuo to give an aqueous residue. This residue was extracted
with ethyl acetate and the extracts were concentrated in vacuo to give 270 mg of
20 the purified FR225497 substance as a white powder.

CLAIMS

1. A compound of the formula (I):



2. A compound, having the following characteristics :

- 15
- a) Molecular formula : $C_{34}H_{44}N_4O_5$
b) Melting point : 193-194°C
c) Solubility :
Soluble : Methanol, Chloroform, Ethyl acetate
Insoluble : Water, n-Hexane
- 20
- d) Color reaction :
Positive : Ceric sulfate reaction, iodine vapor reaction
Negative : Ninhydrin reaction, ferric chloride reaction,
Molish reaction, Erlich reaction, Dragendorff reaction
- 25
- e) Infrared spectrum :
 $\nu_{\max}(\text{KBr})$: 3340, 3320, 2930, 1710, 1690, 1670, 1660, 1630,
1530, 1510, 1420, 1310, 1170, 1110 cm^{-1}

3. A process for production of the compound of claim 1 or 2, which comprises culturing, in a nutrient medium, a FR225497 substance-producing strain belonging to *Helicoma* and recovering the compound of claim 1 or 2 from a culture broth.
- 30

4. A pharmaceutical composition containing the compound of claim 1 or 2, an active ingredient, in association with a pharmaceutically acceptable,

substantially non-toxic carrier or excipient.

5. A compound of claim 1 or 2 for use as a medicament.

5 6. A use of the compound of claim 1 or 2 for manufacture of a medicament for inhibiting histone deacetylase.

7. A use of the compound of claim 1 or 2 for manufacture of a medicament for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), protozoal infection, organ transplant rejection, autoimmune diseases, or tumor.

8. A use of histone deacetylase inhibitors for manufacture of an immunosuppressant or an antitumor agent.

9. A use of histone deacetylase inhibitors for manufacture of a medicament for treating or preventing organ transplant rejection, autoimmune diseases, or tumor.



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 February 2000 (17.02.2000)

PCT

(10) International Publication Number
WO 00/008048 A3

(51) International Patent Classification⁷: **C07K 5/12,**
A61K 38/07

(21) International Application Number: **PCT/JP99/04148**

(22) International Filing Date: **2 August 1999 (02.08.1999)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
PP 5057 4 August 1998 (04.08.1998) AU

(71) Applicant (for all designated States except US): **FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MORI, Hiroaki [JP/JP]; 5-20-205, Ohmachi, Tsuchiura-shi, Ibaraki 300-0038 (JP). ABE, Fumie [JP/JP]; 2-21-2-1-501, Matsushiro, Tsukuba-shi, Ibaraki 305-0035 (JP).**

YOSHIMURA, Seiji [JP/JP]; 4-21-2-1-404, Matsushiro, Tsukuba-shi, Ibaraki 305-0035 (JP). TAKASE, Shigehiro [JP/JP]; 1-12-10, Sousha, Ishioka-shi, Ibaraki 315-0016 (JP). HINO, Motohiro [JP/JP]; 13-3-1003, Touzaki-cho, Tsuchiura-shi, Ibaraki 300-0031 (JP).

(74) Agent: **TABUSHI, Eiji; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).**

(81) Designated States (national): **BR, CA, CN, JP, KR, US.**

(84) Designated States (regional): **European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).**


Published:

— with international search report

(88) Date of publication of the international search report:
15 August 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **INHIBITOR OF HISTONE DEACETYLASE**



(I)

(57) Abstract: The present invention provides a new compound of formula (I) which has a histone deacetylase inhibiting activity, and a process for production thereof. Also provided is a pharmaceutical composition containing the compound for treating or preventing organ transplant rejections, autoimmune diseases, tumors, and the like.

WO 00/008048 A3

INTERNATIONAL SEARCH REPORT

National Application No

JP 99/04148

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07K5/12 A61K38/07

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 309 696 A (MERCK & CO INC) 6 August 1997 (1997-08-06) page 1 -page 4 page 6	8,9
X	WO 97 35990 A (JAMISON TIMOTHY F ;HARVARD COLLEGE (US); TAUNTON JACK (US); HASSIG) 2 October 1997 (1997-10-02) abstract; claims 80-82	8,9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

4 November 1999

Date of mailing of the international search report

11/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

International Application No

PC P 99/04148

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIJIMA M ET AL: "TRAPOXIN, AN ANTITUMOR CYCLIC TETRAPEPTIDE, IS AN IRREVERSIBLE INHIBITOR OF MAMMALIAN HISTONE DEACETYLASE" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 30, 1993, pages 22429-22435, XP002914497 ISSN: 0021-9258 abstract page 22429, column 2, last paragraph -----	8,9
X	EP 0 406 725 A (SHIONOGI & CO) 9 January 1991 (1991-01-09) page 3, line 19 -----	8,9

INTERNATIONAL SEARCH REPORT

Annex to patent family members

International Application No

PC 99/04148

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2309696 A	06-08-1997	NONE	
WO 9735990 A	02-10-1997	AU 2990597 A	17-10-1997
EP 0406725 A	09-01-1991	JP 3034991 A	14-02-1991
		AT 102955 T	15-04-1994
		DE 69007356 D	21-04-1994
		DE 69007356 T	13-10-1994
		DK 406725 T	02-05-1994
		ES 2053018 T	16-07-1994
		US 5112944 A	12-05-1992